sunitinib sandoz 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
sunitinib teva 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula - sunitinib
sunitinib teva 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
sunitinib teva 37,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 37,5 mg / 1 kapsula - sunitinib
sunitinib sandoz 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula - sunitinib
sunitinib sandoz 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
sunitinib teva 12,5 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 12,5 mg / 1 kapsula - sunitinib
sunitinib teva 25 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 25 mg / 1 kapsula - sunitinib
sunitinib teva 50 mg trde kapsule
sunitinib - kapsula, trda - sunitinib 50 mg / 1 kapsula - sunitinib
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastična sredstva - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.